MY209751A - Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production - Google Patents

Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production

Info

Publication number
MY209751A
MY209751A MYPI2020002460A MYPI2020002460A MY209751A MY 209751 A MY209751 A MY 209751A MY PI2020002460 A MYPI2020002460 A MY PI2020002460A MY PI2020002460 A MYPI2020002460 A MY PI2020002460A MY 209751 A MY209751 A MY 209751A
Authority
MY
Malaysia
Prior art keywords
pyrimidinylamino
polymorphs
production
methods
solid forms
Prior art date
Application number
MYPI2020002460A
Other languages
English (en)
Inventor
Travis Remarchuk
Anantha Sudhakar
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of MY209751A publication Critical patent/MY209751A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MYPI2020002460A 2017-11-21 2018-11-20 Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production MY209751A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762589276P 2017-11-21 2017-11-21
PCT/US2018/062102 WO2019104086A1 (fr) 2017-11-21 2018-11-20 Polymorphes et formes solides d'un composé de pyrimidinylamino-pyrazole, et procédés de production

Publications (1)

Publication Number Publication Date
MY209751A true MY209751A (en) 2025-07-31

Family

ID=66631734

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2020002460A MY209751A (en) 2017-11-21 2018-11-20 Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production

Country Status (24)

Country Link
US (3) US10370361B2 (fr)
EP (1) EP3717473B1 (fr)
JP (1) JP7303821B2 (fr)
KR (1) KR102878525B1 (fr)
CN (1) CN111819174A (fr)
AR (1) AR113893A1 (fr)
AU (1) AU2018372180B2 (fr)
CA (1) CA3083022A1 (fr)
CL (1) CL2020001346A1 (fr)
CO (1) CO2020006206A2 (fr)
CR (1) CR20200216A (fr)
EA (1) EA202091279A1 (fr)
ES (1) ES2975319T3 (fr)
IL (1) IL274824B1 (fr)
JO (1) JOP20200128A1 (fr)
MA (1) MA51222A (fr)
MX (1) MX2020005332A (fr)
MY (1) MY209751A (fr)
PE (1) PE20210157A1 (fr)
PH (1) PH12020550700A1 (fr)
SG (1) SG11202004733WA (fr)
TW (1) TWI823878B (fr)
UA (1) UA126414C2 (fr)
WO (1) WO2019104086A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2975319T3 (es) * 2017-11-21 2024-07-04 Denali Therapeutics Inc Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producción
CA3086182A1 (fr) 2017-12-20 2019-06-27 Denali Therapeutics Inc. Procede de preparation de composes pyrimidinyl-4-aminopyrazole
AU2021371136A1 (en) 2020-10-29 2023-05-11 Merck Sharp & Dohme Llc N-linked isoquinoline amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
WO2023174946A1 (fr) 2022-03-15 2023-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthode précoce et non invasive d'évaluation du risque de maladie de parkinson chez un sujet
US12272712B2 (en) 2022-05-14 2025-04-08 Xintec Inc. Chip package and method for forming a chip package having first and second stack of dummy metal layers surround the sensing region

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202091303A3 (ru) 2010-05-21 2021-05-31 Инсайт Холдингс Корпорейшн Композиция ингибитора jak для местного применения
AU2011260323A1 (en) 2010-06-04 2012-11-15 F. Hoffmann-La Roche Ag Aminopyrimidine derivatives as LRRK2 modulators
GB201015949D0 (en) 2010-09-22 2010-11-03 Medical Res Council Technology Compounds
KR101566091B1 (ko) * 2010-11-10 2015-11-04 에프. 호프만-라 로슈 아게 Lrrk2 조절제로서 피라졸 아미노피리미딘 유도체
JP6185925B2 (ja) 2011-11-29 2017-08-23 ジェネンテック， インコーポレイテッド Ｌｒｒｋ２モジュレーターとしてのアミノピリミジン誘導体
US9145402B2 (en) 2011-11-29 2015-09-29 Genentech, Inc. Aminopyrimidine derivatives as LRRK2 modulators
AR089182A1 (es) 2011-11-29 2014-08-06 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
US8791130B2 (en) 2011-11-29 2014-07-29 Genentech, Inc. Aminopyrimidine derivatives as LRRK2 modulators
CN104271569B (zh) 2012-05-03 2016-08-24 霍夫曼-拉罗奇有限公司 作为lrrk2调节剂的吡唑氨基嘧啶衍生物
WO2013164323A1 (fr) 2012-05-03 2013-11-07 F. Hoffmann-La Roche Ag Dérivés de pyrazole aminopyrimidine en tant que modulateurs de lrrk2 destinés à être utilisés dans le traitement de la maladie de parkinson
PT3472153T (pt) 2016-06-16 2021-12-31 Denali Therapeutics Inc Pirimidin-2-ilamino-1h-pirazóis como inibidores de lrrk2 para uso no tratamento de distúrbios neurodegenerativos
ES2975319T3 (es) * 2017-11-21 2024-07-04 Denali Therapeutics Inc Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producción

Also Published As

Publication number Publication date
JOP20200128A1 (ar) 2020-05-21
IL274824A (en) 2020-07-30
US20190315723A1 (en) 2019-10-17
IL274824B1 (en) 2026-05-01
AU2018372180A1 (en) 2020-06-18
AU2018372180B2 (en) 2023-08-17
PE20210157A1 (es) 2021-01-26
MX2020005332A (es) 2021-01-08
US20210087176A1 (en) 2021-03-25
UA126414C2 (uk) 2022-09-28
EP3717473A1 (fr) 2020-10-07
MA51222A (fr) 2020-10-07
JP2021504450A (ja) 2021-02-15
TW201925190A (zh) 2019-07-01
CR20200216A (es) 2021-03-19
JP7303821B2 (ja) 2023-07-05
US20190194170A1 (en) 2019-06-27
US10370361B2 (en) 2019-08-06
US10851088B2 (en) 2020-12-01
CO2020006206A2 (es) 2020-08-10
KR20200089713A (ko) 2020-07-27
WO2019104086A1 (fr) 2019-05-31
EA202091279A1 (ru) 2020-08-19
EP3717473B1 (fr) 2024-01-10
AR113893A1 (es) 2020-06-24
US11427571B2 (en) 2022-08-30
CN111819174A (zh) 2020-10-23
BR112020010215A2 (pt) 2020-11-03
ES2975319T3 (es) 2024-07-04
TWI823878B (zh) 2023-12-01
NZ764730A (en) 2024-11-29
SG11202004733WA (en) 2020-06-29
CL2020001346A1 (es) 2020-11-20
EP3717473A4 (fr) 2021-07-07
CA3083022A1 (fr) 2019-05-31
KR102878525B1 (ko) 2025-10-31
PH12020550700A1 (en) 2021-04-12

Similar Documents

Publication Publication Date Title
PH12020550700A1 (en) Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production
SA520411007B1 (ar) مركبات مضادة للتكاثر وطرق لاستخدامها
MX2020002060A (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos.
MY199931A (en) 3-substituted propionic acids as alpha v integrin inhibitors
IL279101A (en) Salts of spiafatrin are accepted in pharmacies
MX2022001410A (es) Composiciones y metodos de uso de 2-(4-clorofenil)-n-((2-(2,6-diox opiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamid a.
PH12018550120B1 (en) Steroid derivative fxr agonist
MY193177A (en) Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use therepf
WO2016044641A3 (fr) Inhibiteurs de carm1 et leurs utilisations
MX394540B (es) Polimorfos y formas solidas de la (s)-2-((2-((s)-4-(difluorometil)-2-oxooxazolidin-3-il)-5,6-dihidrobenzo[f]imidazo[1,2-d] [1,4]oxazepin-9-il)amino)propanamida, y metodos de produccion.
WO2014192030A3 (fr) Procédé amélioré pour la préparation de l'étéxilate de dabigatran et sels d'addition acide pharmaceutiquement acceptables de celui-ci
EP4275707A3 (fr) Formulations de 2-(4-chlorophényl)-n-((2-(2,6-dioxopipéridin-3-yl)-1-oxoisoindolin-5-yl)méthyl)-2,2-difluoroacétamide
PH12017500029A1 (en) 4,5-dihydroisoxazole derivatives as nampt inhibitors
MX2021007800A (es) Composiciones y metodos para usar 2-(4-clorofenil)-n-((2-(2,6-diox opiperidin-3-il)-1-ox-oisoindolin-5il)metil)-2,2-difluoroacetamid a.
WO2016023028A3 (fr) Inhibiteurs de la kinase du récepteur couplé aux protéines g 2 et procédés d'utilisation de ceux-ci
MY193041A (en) Novel fused imidazobenzothiazole compounds
WO2015111085A3 (fr) Procédés de préparation d'eltrombopag et sels pharmaceutiquement acceptables, solvates et intermédiaires de celui-ci
PH12021550456A1 (en) Crystalline forms of a quinazole compound and its hydrochloride salts
ES3065261T3 (en) Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof
PH12017501532A1 (en) Crystalline forms of a pyrrolopyridine compound
NZ748942A (en) Pyrazolylaminobenzimidazole derivatives as jak inhibitors
PH12017500323B1 (en) P38 map kinase inhibiting indanyl urea compounds
PH12020500385A1 (en) A process for preparation of triaminopyrimidine compound and intermediates thereof
MY200253A (en) (2s)-1-[4-(3,4-dichlorophenyl)piperidin-l-yl]-3-[2-(5-methyl-l,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol or its metabolite for treating anxiety disorders
MX2021014705A (es) Formulacion de liberacion modificada de un compuesto de pirimidinilamino-pirazol y metodos de tratamiento.